

Jaime Feliu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9511293/publications.pdf>

Version: 2024-02-01

104
papers

2,282
citations

218677

26
h-index

265206

42
g-index

109
all docs

109
docs citations

109
times ranked

3014
citing authors

#	ARTICLE	IF	CITATIONS
1	BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial. <i>Nature Medicine</i> , 2020, 26, 878-885.	30.7	297
2	XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer. <i>British Journal of Cancer</i> , 2006, 94, 969-975.	6.4	114
3	Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: Beyond KRAS mutations. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 85, 45-81.	4.4	90
4	Efficacy of oral tegafur modulation by uracil and leucovorin in advanced colorectal cancer. A phase II study. <i>European Journal of Cancer</i> , 1995, 31, 2215-2219.	2.8	82
5	ABCA1 overexpression worsens colorectal cancer prognosis by facilitating tumour growth and caveolin-1-dependent invasiveness, and these effects can be ameliorated using the BET inhibitor apabetalone. <i>Molecular Oncology</i> , 2018, 12, 1735-1752.	4.6	79
6	Symptom Clusters in Advanced Cancer. <i>Journal of Pain and Symptom Management</i> , 2011, 42, 24-31.	1.2	78
7	Development and Validation of a Prognostic Nomogram for Terminally Ill Cancer Patients. <i>Journal of the National Cancer Institute</i> , 2011, 103, 1613-1620.	6.3	77
8	Preoperative Chemotherapy in Patients With Intermediate-Risk Rectal Adenocarcinoma Selected by High-Resolution Magnetic Resonance Imaging: The GEMCAD 0801 Phase II Multicenter Trial. <i>Oncologist</i> , 2014, 19, 1042-1043.	3.7	66
9	Uracil and tegafur modulated with leucovorin. , 1997, 79, 1884-1889.		62
10	Gemcitabine plus vinorelbine in nonsmall cell lung carcinoma patients age 70 years or older or patients who cannot receive cisplatin. , 1999, 86, 1463-1469.		60
11	Neoadjuvant therapy of rectal carcinoma with UFT leucovorin plus radiotherapy. <i>Annals of Oncology</i> , 2002, 13, 730-736.	1.2	60
12	Untreated metastatic diffuse gastric adenocarcinoma (DGAC): Randomized phase III study of S-1 and cisplatin vs. 5-FU and cisplatin (the DIGEST trial).. <i>Journal of Clinical Oncology</i> , 2015, 33, 4015-4015.	1.6	56
13	Functional proteomics outlines the complexity of breast cancer molecular subtypes. <i>Scientific Reports</i> , 2017, 7, 10100.	3.3	50
14	Liquid Biopsy in Pancreatic Cancer: Are We Ready to Apply It in the Clinical Practice?. <i>Cancers</i> , 2021, 13, 1986.	3.7	43
15	SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer (2018). <i>Clinical and Translational Oncology</i> , 2019, 21, 46-54.	2.4	40
16	Analysis of the Concordance in the EGFR Pathway Status Between Primary Tumors and Related Metastases of Colorectal Cancer Patients: Implications for Cancer Therapy. <i>Current Cancer Drug Targets</i> , 2012, 12, 124-131.	1.6	38
17	Combination of low-dose cisplatin and gemcitabine for treatment of elderly patients with advanced non-small-cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2003, 52, 247-252.	2.3	37
18	Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial. <i>Clinical Cancer Research</i> , 2021, 27, 5020-5027.	7.0	37

#	ARTICLE	IF	CITATIONS
19	Phase II trial of gemcitabine and UFT modulated by leucovorin in patients with advanced pancreatic carcinoma. <i>Cancer</i> , 2000, 89, 1706-1713.	4.1	34
20	Correlation of Hypertension and Proteinuria with Outcome in Elderly Bevacizumab-Treated Patients with Metastatic Colorectal Cancer. <i>PLoS ONE</i> , 2015, 10, e0116527.	2.5	34
21	Phase II study of a fixed dose-rate infusion of gemcitabine associated with uracil/tegafur in advanced carcinoma of the pancreas. <i>Annals of Oncology</i> , 2002, 13, 1756-1762.	1.2	31
22	Phase II randomised trial of raltitrexed+oxaliplatin vs raltitrexed+irinotecan as first-line treatment in advanced colorectal cancer. <i>British Journal of Cancer</i> , 2005, 93, 1230-1235.	6.4	31
23	A phase III trial comparing oral S-1/cisplatin and intravenous 5-fluorouracil/cisplatin in patients with untreated diffuse gastric cancer. <i>Annals of Oncology</i> , 2017, 28, 2142-2148.	1.2	30
24	First-line bevacizumab and capecitabine+oxaliplatin in elderly patients with mCRC: GEMCAD phase II BECOX study. <i>British Journal of Cancer</i> , 2014, 111, 241-248.	6.4	29
25	Clinical guideline SEOM: hepatocellular carcinoma. <i>Clinical and Translational Oncology</i> , 2015, 17, 988-995.	2.4	29
26	Management of the toxicity of chemotherapy and targeted therapies in elderly cancer patients. <i>Clinical and Translational Oncology</i> , 2020, 22, 457-467.	2.4	29
27	A Combined Strategy of SAGE and Quantitative PCR Provides a 13-Gene Signature that Predicts Preoperative Chemoradiotherapy Response and Outcome in Rectal Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 4145-4154.	7.0	28
28	SEOM Clinical Guideline for the treatment of pancreatic cancer (2016). <i>Clinical and Translational Oncology</i> , 2016, 18, 1172-1178.	2.4	27
29	Can we avoid the toxicity of chemotherapy in elderly cancer patients?. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 131, 16-23.	4.4	25
30	SEOM clinical guidelines for pancreatic and biliary tract cancer (2020). <i>Clinical and Translational Oncology</i> , 2021, 23, 988-1000.	2.4	23
31	Molecular characterization of breast cancer cell response to metabolic drugs. <i>Oncotarget</i> , 2018, 9, 9645-9660.	1.8	22
32	Incidence of venous thromboembolic events in cancer patients receiving immunotherapy: a single-institution experience. <i>Clinical and Translational Oncology</i> , 2021, 23, 1245-1252.	2.4	21
33	Predicting Chemotherapy Toxicity in Older Patients with Cancer: A Multicenter Prospective Study. <i>Oncologist</i> , 2020, 25, e1516-e1524.	3.7	20
34	Irinotecan plus raltitrexed as first-line treatment in advanced colorectal cancer: a phase II study. <i>British Journal of Cancer</i> , 2004, 90, 1502-1507.	6.4	19
35	Novel molecular targeted therapies for patients with neurofibromatosis type 1 with inoperable plexiform neurofibromas: a comprehensive review. <i>ESMO Open</i> , 2021, 6, 100223.	4.5	18
36	Descriptive analysis of clinical factors affecting terminally ill cancer patients. <i>Supportive Care in Cancer</i> , 2009, 17, 261-269.	2.2	17

#	ARTICLE	IF	CITATIONS
37	Neoadjuvant capecitabine, oxliplatin, and bevacizumab (CAPOX-B) in intermediate-risk rectal cancer (RC) patients defined by magnetic resonance (MR): GEMCAD 0801 trial.. Journal of Clinical Oncology, 2012, 30, 3586-3586.	1.6	17
38	Neoadjuvant chemotherapy with or without radiotherapy versus upfront surgery for resectable pancreatic adenocarcinoma: a meta-analysis of randomized clinical trials. ESMO Open, 2022, 7, 100485.	4.5	17
39	UFT (tegafurâ€“uracil) in rectal cancer. Annals of Oncology, 2008, 19, 1371-1378.	1.2	16
40	Delphi consensus of an expert committee in oncogeriatrics regarding comprehensive geriatric assessment in seniors with cancer in Spain. Journal of Geriatric Oncology, 2018, 9, 337-345.	1.0	16
41	Gp-100 as a Novel Therapeutic Target in Uveal Melanoma. Cancers, 2021, 13, 5968.	3.7	16
42	Phase I study of UFT plus leucovorin in advanced colorectal cancer: a double modulation proposal. Anticancer Research, 1993, 13, 759-62.	1.1	16
43	Effectiveness and safety of aflibercept for metastatic colorectal cancer: retrospective review within an early access program in Spain. Clinical and Translational Oncology, 2017, 19, 498-507.	2.4	15
44	Undertreatment and overtreatment in older patients treated with chemotherapy. Journal of Geriatric Oncology, 2021, 12, 381-387.	1.0	14
45	Phase II clinical trial of nab-paclitaxel plus gemcitabine in elderly patients with previously untreated locally advanced or metastatic pancreatic adenocarcinoma: the BIBABRAX study. Cancer Chemotherapy and Pharmacology, 2021, 87, 543-553.	2.3	14
46	Prospective Biomarker Study in Advanced RAS Wild-Type Colorectal Cancer: POSIBA Trial (GEMCAD) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	3.7	12
47	Clinical Impact of Circulating Tumor RAS and BRAF Mutation Dynamics in Patients With Metastatic Colorectal Cancer Treated With First-Line Chemotherapy Plus Antiâ€“Epidermal Growth Factor Receptor Therapy. JCO Precision Oncology, 2019, 3, 1-16.	3.0	12
48	VITAL phase 2 study: Upfront 5â€“fluorouracil, mitomycinâ€“C, panitumumab and radiotherapy treatment in nonmetastatic squamous cell carcinomas of the anal canal (GEMCAD 09â€“02). Cancer Medicine, 2020, 9, 1008-1016.	2.8	12
49	Prognostic value of neutrophil-to-lymphocyte ratio and other inflammatory markers in patients with high-risk soft tissue sarcomas. Clinical and Translational Oncology, 2020, 22, 1849-1856.	2.4	12
50	Prognostic value of neutrophil-to-lymphocyte ratio in advanced cancer patients receiving immunotherapy. Clinical and Translational Oncology, 2021, 23, 1185-1192.	2.4	12
51	Understanding the immune response and the current landscape of immunotherapy in pancreatic cancer. World Journal of Gastroenterology, 2021, 27, 6775-6793.	3.3	12
52	A Phase I, Dose-Finding Study of Sorafenib in Combination with Gemcitabine and Radiation Therapy in Patients with Unresectable Pancreatic Adenocarcinoma: A Grupo EspaÃ±ol Multidisciplinario en CÃ¡ncer Digestivo (GEMCAD) Study. PLoS ONE, 2014, 9, e82209.	2.5	11
53	Comparison of risk classification between EndoPredict and MammaPrint in ER-positive/HER2-negative primary invasive breast cancer. PLoS ONE, 2017, 12, e0183452.	2.5	11
54	Recommendations for SIR-Spheres Y-90 resin microspheres in chemotherapy-refractory/intolerant colorectal liver metastases. Future Oncology, 2017, 13, 2065-2082.	2.4	10

#	ARTICLE	IF	CITATIONS
55	Prediction of Unplanned Hospitalizations in Older Patients Treated with Chemotherapy. <i>Cancers</i> , 2021, 13, 1437.	3.7	10
56	Multiplexed magnetic beads-assisted amperometric bioplatfoms for global detection of methylations in nucleic acids. <i>Analytica Chimica Acta</i> , 2021, 1182, 338946.	5.4	10
57	Prediction of Chemotoxicity, Unplanned Hospitalizations and Early Death in Older Patients with Colorectal Cancer Treated with Chemotherapy. <i>Cancers</i> , 2022, 14, 127.	3.7	9
58	Docetaxel and mitomycin as second-line treatment in advanced non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 58, 527-531.	2.3	8
59	Combination therapy with docetaxel and low dose of cisplatin in elderly patients with advanced non-small cell lung cancer: multicenter phase II study. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 63, 403-409.	2.3	8
60	Comprehensive Characterization of the Mutational Landscape in Localized Anal Squamous Cell Carcinoma. <i>Translational Oncology</i> , 2020, 13, 100778.	3.7	8
61	Development and Validation of an Early Mortality Risk Score for Older Patients Treated with Chemotherapy for Cancer. <i>Journal of Clinical Medicine</i> , 2021, 10, 1615.	2.4	8
62	Coexpression of p-IGF-1R and MMP-7 Modulates Panitumumab and Cetuximab Efficacy in RAS Wild-Type Metastatic Colorectal Cancer Patients. <i>Neoplasia</i> , 2018, 20, 678-686.	5.3	7
63	Chemotherapy and Targeted Agents in the Treatment of Elderly Patients with Metastatic Colorectal Cancer. <i>Journal of Clinical Medicine</i> , 2020, 9, 4015.	2.4	7
64	Eribulin activity in soft tissue sarcoma monolayer and three-dimensional cell line models: could the combination with other drugs improve its antitumoral effect?. <i>Cancer Cell International</i> , 2021, 21, 646.	4.1	6
65	Fixed dose-rate infusion of gemcitabine in combination with cisplatin and UFT in advanced carcinoma of the pancreas. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 58, 419-426.	2.3	5
66	Hepatocellular and biliary tract carcinomas: SEOM clinical guidelines. <i>Clinical and Translational Oncology</i> , 2011, 13, 536-544.	2.4	5
67	Gene expression differences in primary colorectal tumors and matched liver metastases: chemotherapy related or tumoral heterogeneity?. <i>Clinical and Translational Oncology</i> , 2015, 17, 322-329.	2.4	5
68	Exploratory findings from a prematurely closed international, multicentre, academic trial: RAVELLO, a phase III study of regorafenib versus placebo as maintenance therapy after first-line treatment in RAS wild-type metastatic colorectal cancer. <i>ESMO Open</i> , 2019, 4, e000519.	4.5	5
69	Efficacy of capecitabine when used concomitantly with proton pump inhibitors in cancer patients: a systematic review. <i>Clinical and Translational Oncology</i> , 2020, 22, 1288-1294.	2.4	5
70	Bevacizumab in recurrent ovarian cancer: could it be particularly effective in patients with clear cell carcinoma?. <i>Clinical and Translational Oncology</i> , 2021, 23, 536-542.	2.4	5
71	Trybeca-1: A randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with pancreatic adenocarcinoma (NCT03665441).. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS471-TPS471.	1.6	5
72	Consensus on the treatment of pancreatic cancer in Spain. <i>Clinical and Translational Oncology</i> , 2009, 11, 290-301.	2.4	4

#	ARTICLE	IF	CITATIONS
73	Recommendations and expert opinion on the adjuvant treatment of colon cancer in Spain. <i>Clinical and Translational Oncology</i> , 2011, 13, 798-804.	2.4	4
74	Management of colorectal cancer patients after resection of liver metastases: can we offer a tailored treatment?. <i>Clinical and Translational Oncology</i> , 2012, 14, 641-658.	2.4	4
75	Genetic Profile and Functional Proteomics of Anal Squamous Cell Carcinoma: Proposal for a Molecular Classification. <i>Molecular and Cellular Proteomics</i> , 2020, 19, 690-700.	3.8	4
76	Yttrium-90 transarterial radioembolization in patients with gastrointestinal malignancies. <i>Clinical and Translational Oncology</i> , 2022, 24, 796-808.	2.4	4
77	Prognosis Stratification Tools in Early-Stage Endometrial Cancer: Could We Improve Their Accuracy?. <i>Cancers</i> , 2022, 14, 912.	3.7	4
78	Phase II study of neoadjuvant treatment of rectal cancer with oxaliplatin, raltitrexed and radiotherapy. <i>Journal of Clinical Oncology</i> , 2004, 22, 3746-3746.	1.6	3
79	Radiologic and pathologic prognostic factors after neoadjuvant chemotherapy for T3 rectal cancer (RC): 3-year update GEMCAD 0801-trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, 643-643.	1.6	3
80	Abstract CT177: A multi-center phase 2a trial of the CXCR4 inhibitor motixafortide (BL-8040) (M) in combination with pembrolizumab (P) and chemotherapy (C), in patients with metastatic pancreatic adenocarcinoma (mPDAC). <i>Cancer Research</i> , 2021, 81, CT177-CT177.	0.9	2
81	First-line treatment with panitumumab plus FOLFIRI in elderly patients with <i>RAS/BRAF</i> wild-type unresectable metastatic colorectal cancer and good performance status: OPALO trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS3618-TPS3618.	1.6	2
82	Identification of Carcinogenesis and Tumor Progression Processes in Pancreatic Ductal Adenocarcinoma Using High-Throughput Proteomics. <i>Cancers</i> , 2022, 14, 2414.	3.7	2
83	Should be NICE have a Spanish NICE?. <i>Clinical and Translational Oncology</i> , 2013, 15, 501-502.	2.4	1
84	Description of the genetic variants identified in a cohort of patients diagnosed with localized anal squamous cell carcinoma and treated with panitumumab. <i>Scientific Reports</i> , 2021, 11, 7402.	3.3	1
85	Prognostic factors in advanced pancreatic ductal adenocarcinoma patients-receiving second-line treatment: a single institution experience. <i>Clinical and Translational Oncology</i> , 2021, 23, 1838-1846.	2.4	1
86	Phase II study of neoadjuvant treatment of rectal cancer with oxaliplatin, raltitrexed and radiotherapy. <i>Journal of Clinical Oncology</i> , 2004, 22, 3746-3746.	1.6	1
87	Efficacy and safety of the combination of aflibercept with fluorouracil, leucovorin, and irinotecan in patients aged 70 years and older with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen in Spain: A retrospective multicenter cohort study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 124-124.	1.6	1
88	Clinicopathological characteristics and outcomes of patients with deficient mismatch repair colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 181-181.	1.6	1
89	Are we changing the way we treat older colorectal cancer patients? An update on therapeutic management strategies. <i>Colorectal Cancer</i> , 2013, 2, 279-283.	0.8	0
90	Situation, challenges, and SEOM recommendations for the future of undergraduate education in Oncology in Spain. <i>Clinical and Translational Oncology</i> , 2020, 22, 1049-1058.	2.4	0

#	ARTICLE	IF	CITATIONS
91	Rondas multidisciplinares en oncología y hematología: ¿son superiores a los equipos de respuesta rápida?. Medicina Intensiva, 2021, 45, 127-128.	0.7	0
92	Survival prediction in terminally ill cancer patients: Description and validation of a new predictive score. Journal of Clinical Oncology, 2009, 27, 9595-9595.	1.6	0
93	Comparison of magnetic resonance imaging and histopathological response to neoadjuvant chemotherapy in locally advanced rectal cancer: The GEMCAD 0801 trial.. Journal of Clinical Oncology, 2012, 30, e14097-e14097.	1.6	0
94	On-line breath analysis of volatile organic compounds as a method for colorectal cancer detection.. Journal of Clinical Oncology, 2012, 30, 1570-1570.	1.6	0
95	Correlation of hypertension and proteinuria with outcomes in elderly bevacizumab (BEV)-treated patients with metastatic colorectal cancer (mCRC): Analysis of the BECOX and BECA studies.. Journal of Clinical Oncology, 2013, 31, 3589-3589.	1.6	0
96	Early onset hypothyroidism as a predictor for progression-free survival (PFS) and overall survival (OS) benefit in patients with advanced renal cell carcinoma treated with first-line sunitinib.. Journal of Clinical Oncology, 2014, 32, e15564-e15564.	1.6	0
97	¿First chemotherapy or first local approach for liver-only synchronous metastasis rectal cancer? A single institution experience.. Journal of Clinical Oncology, 2015, 33, 780-780.	1.6	0
98	Predictive serum biomarkers in metastatic colorectal cancer (mCRC) patients treated in the BECOX trial with oxaliplatin-capecitabine (CAPOX) plus bevacizumab (BVZ) (GEMCAD 09-01).. Journal of Clinical Oncology, 2015, 33, e14647-e14647.	1.6	0
99	Predictive factors of early death after a comprehensive geriatric assessment in elderly cancer patients.. Journal of Clinical Oncology, 2015, 33, e20530-e20530.	1.6	0
100	Predictive factors of grade 3-5 toxicity in elderly cancer patients treated with chemotherapy: A prospective multicenter study (TEP study: Toxicity in Elderly Patient).. Journal of Clinical Oncology, 2015, 33, e20535-e20535.	1.6	0
101	Gene expression markers of resistance to capecitabine-oxaliplatin-bevacizumab treatment in metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2015, 33, e14555-e14555.	1.6	0
102	Prospective biomarker validation trial evaluating the prognostic role of the combined expression of phospho-insulin growth factor receptor-1 and matrilysin in KRAS (exon 2) wild-type (WT) metastatic colorectal cancer (mCRC) patients treated with FOLFOX-6 plus panitumumab as first-line therapy [PULSE trial (GEMCAD 09-03)].. Journal of Clinical Oncology, 2016, 34, 583-583.	1.6	0
103	Long-term cancer survivors: Satisfaction with medical care and information received during the diagnosis and treatment of cancer.. Journal of Clinical Oncology, 2017, 35, e21573-e21573.	1.6	0
104	Phase II study of panitumumab, 5-fluorouracil, mitomycin-c and radiotherapy treatment in patients with non-metastatic squamous cell carcinoma of the anal canal: safety and efficacy results (VITAL) Tj ETQq0 0 0 rgBTdOverlock 10 Tf 50		